FibroGen, Inc. today announced the appointment of K. Peony Yu, M.D., as
Vice President, Clinical Development. Dr. Yu brings to FibroGen
expertise in design and execution of all phases of clinical development
programs, including clinical and regulatory strategy, interactions with
regulatory authorities in the US and EU, as well as experience with
successful leadership of clinical teams.
Dr. Yu was most recently Vice President, Clinical Research, at Anesiva,
Inc. where she was responsible for management of clinical research,
statistics/data management, clinical operations, and medical
affairs/medical information for all clinical programs, including the
late-stage clinical development and approval of Zingo™, a drug-device
combination for pain management. Prior to Anesiva, Dr. Yu was Director,
Clinical Development, at ALZA Corporation (a subsidiary of Johnson &
Johnson) where she was Global Clinical Lead for IONSYS, a drug-device
combination for post-operative pain, and led a successful New Drug
Application resubmission with the U.S. Food & Drug Administration and
multiple interactions with European regulatory authorities resulting in
marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held
previous posts at Pain Therapeutics, Inc., and at Elan Pharmaceuticals.
“Peony’s experience in leading multifunctional clinical teams with
proven success in advancing investigational products through all stages
of clinical development through regulatory approval will be an important
asset to FibroGen,” said Frank H. Valone, M.D., Chief Medical Officer of
FibroGen. “We look forward to her leadership of our multiple clinical
programs in the U.S. and globally.”
Dr. Yu received a B.S. in Chemical Engineering and an M.D. both from the
University of California, Davis, followed by residency training at
Stanford Medical School.
About FibroGen
FibroGen, Inc. is a biotechnology-based drug discovery company using its
expertise in the fields of tissue fibrosis, connective tissue growth
factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover,
develop, and commercialize novel therapeutics for fibrotic disorders,
diabetic complications, anemia, conditions associated with tissue damage
or injury, cancer, and other areas of unmet medical need. FibroGen also
develops and produces recombinant human collagens and gelatins using
unique production technology that provides the basis for FibroGen's
proprietary cosmetic dermal filler and biomaterials supply business.
For more information about FibroGen, Inc., please visit www.fibrogen.com.
For FibroGen, Inc.
Laura Hansen, Ph.D., 415-978-1433
Director,
Corporate Communications
lhansen@fibrogen.com
